论文部分内容阅读
目的:观察缓释二氢奎尼丁血药浓度与QTc间期、QT间期离散度、QUc间期等参数的相关性。方法:40例心房颤动病人口服缓释二氢奎尼丁。心电图记录采用50mm/s纸速,2倍电压的方法。血药浓度测定采用TDX方法。结果:①缓释二氢奎尼丁疗效明显,转复窦性心律54.6%(6/11例),预防心房颤动复发有效率71.4%(25/35例)。②血药浓度与QUc间期高度相关(r=0.93,P<0.01)。③服药前、后心肌复极离散度比较无差异。用药后U波发生率明显增加,但未见药物的致心律失常作用。结论:缓释二氢奎尼丁血药浓度与QUc间期高度相关。
OBJECTIVE: To observe the correlation between the release of dihydroquinidine and QTc interval, QT interval dispersion, QUc interval and other parameters. Methods: 40 patients with atrial fibrillation oral sustained release of dihydroquinidine. ECG recording using 50mm / s paper speed, 2 times the voltage method. Blood concentration determination using TDX method. Results: (1) The slow release of dihydroquinidine markedly improved the recovery of sinus rhythm (54.6%, 6/11 cases) and the prevention of recurrent atrial fibrillation (71.4%, 25/35). ② plasma concentration and QUc interval highly correlated (r = 0.93, P <0.01). ③ medication before and after the myocardial repolarization dispersion no difference. U wave incidence after treatment increased significantly, but no drug induced arrhythmia. CONCLUSIONS: The sustained-release dihydroquinidine serum concentration is highly correlated with the QUc interval.